The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
 
David S. Hong
No Relationships to Disclose
 
Van Karlyle Morris
No Relationships to Disclose
 
Badi Edmond El Osta
No Relationships to Disclose
 
Siqing Fu
No Relationships to Disclose
 
Michael J. Overman
No Relationships to Disclose
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Vivek Subbiah
No Relationships to Disclose
 
Bryan K. Kee
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); Celgene (Inst); EMD Serono (Inst); Foundation Medicine (Inst); NCCN (Inst)
 
Ralph Zinner
No Relationships to Disclose
 
David R. Fogelman
Stock and Other Ownership Interests - GTx
Consulting or Advisory Role - Incyte
 
Jorge Bellido
No Relationships to Disclose
 
Imad Shureiqi
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche; Sysmex
Consulting or Advisory Role - Genentech; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical
 
Scott Kopetz
Consulting or Advisory Role - Agendia; Amgen; Array BioPharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merrimack; Roche; Sanofi; Sysmex; Taiho Pharmaceutical
Research Funding - Agendia; Amgen; Biocartis; GlaxoSmithKline; Guardant Health; Roche; Sanofi; Sysmex